A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors - MK-1200-002

Merck Sharp & Dohme LLC0 个研究点目标入组 247 人开始时间: 2023年12月22日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Confirmed advanced (unresectable and/or metastatic) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma, Participants who experienced Adverse Events (AEs) due to previous anticancer therapies must have recovered to < Grade 1 or baseline, Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy, Received and progressed on or after 1 or 2 prior lines of therapy

•Active severe digestive disease, Known active central nervous system (CNS) metastases and/or carcinomatous meningitis, Active infection requiring systemic therapy, History of known Hepatitis B or known active Hepatitis C viral infection, Have not adequately recovered from major surgery or have ongoing surgical complications, History of major cardiovascular diseases, History of acute myocardial infarction; unstable angina; stroke or transient ischemic attack within 6 months prior to the first dose of study intervention, Cardiac pacemaker use, Diabetes or hypertension that cannot be controlled by medication, HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease, Received prior systemic anticancer therapy including investigational agents within 4 weeks before study intervention, Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids, Known additional malignancy that is progressing or has required active treatment within the past 2 years

发起方